By combining the mTOR inhibitor rapamycin with lenvatinib, we found that rapamycin not only enhanced the sensitivity of HCC cells to lenvatinib but also reduced the expression of IL-1β. The gene discussed is IL1B; the disease is hepatocellular carcinoma.